NCT04701658

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 109 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein. These participants will be matched to similar COVID-19 patients who received other treatment at a local medical center. All participants will be followed to learn how their disease responds. Participation could last about 3 months and includes two required visits to the study site, with the remainder of assessments performed by phone or by medical record review.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Bamlanivimab	Administered intravenously.

Timeline

• Start date: 2021-02-01
• Primary completion: 2021-06-22
• Completion: 2021-06-22
• First posted: 2021-01-08
• Last updated: 2021-11-16
• Results posted: 2021-11-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study